Last updated on September 2017

A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stage III (IIIB or IIIC) Colon Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    The Eastern Cooperative Oncology Group (ECOG) performance status must be 0-1
    There must be histologic confirmation of high risk, adenocarcinoma of the colon
    defined as AJCC 7th Edition Stage IIIB or IIIC.
    The patient must have had an en bloc complete gross resection of tumor (curative
    resection) by open laparotomy or laparoscopically-assisted colectomy. The distal
    extent of the tumor must have been greater than or equal to 12 cm from the anal verge.
    (Patients who have had a two-stage surgical procedure to first provide a decompression
    colostomy and then in a later procedure to have a surgical resection are eligible.)
    Imaging (positron emission tomography/computed tomography (PET/CT) scan, CT scan, or
    magnetic resonance imaging (MRI)) of chest, abdomen, and pelvis must be performed
    within 90 days prior to randomization and must demonstrate no evidence of metastatic
    disease. If findings noted in imaging study reports are equivocal, the determination
    of whether or not the findings represent metastatic disease will be at the
    investigator's discretion.
    The patient must be able to swallow oral medication.
    The patient must have completed at least 4 months of adjuvant chemotherapy (i.e.,
    FOLFOX, CapeOx, or other, such as 5-fluorouracil, leucovorin, oxaliplatin (FLOX),
    5-fluorouracil/leucovorin (5FU/LV), capecitabine).
    The interval between completion of standard adjuvant chemotherapy and randomization
    must be less than or equal to 60 days.
    Blood counts performed within 28 days prior to randomization must meet the following
    criteria:
    Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
    platelet count must be greater than or equal to 100,000/mm3; and
    hemoglobin must be greater than or equal to 9 g/dL.
    The following criteria for evidence of adequate hepatic function performed within 4
    weeks prior to randomization must be met:
    total bilirubin must be less than or equal to 1.5 x upper limit of normal (ULN);
    and
    alkaline phosphatase must be less than or equal to 2 x ULN; and
    Asparate aminotransferase (AST) and alanine aminotransferase (ALT) must be less
    than or equal to 2 x ULN for the lab. (Note: If AST and/or ALT greater than ULN,
    erologic testing for Hepatitis B and C must be performed and results must be
    negative.)
    Lipase performed within 28 days of randomization must be less than or equal to 1.5 x
    ULN for the lab.
    Serum creatinine performed within 28 days of randomization must be less than or equal
    to 1.5 x ULN for the lab.
    Urinalysis dipstick for urinary protein performed within 28 days prior to
    randomization must be 0-1+ protein. If urine dipstick result is greater than or equal
    to 2+ protein, a 24-hour urine protein must be less than 1.0 g/24 hours.
    Glomerular filtration rate (GFR) must be greater than or equal to 30 mL/min/1.73 m2
    according to the Modified Diet in Renal Disease (MDRD) abbreviated formula.
    International normalized ratio of prothrombin time must be less than or equal to 1.5
    times the ULN. Patients who are therapeutically treated with an agent such as warfarin
    or heparin will be allowed to participate if no underlying abnormality in coagulation
    parameters exists per medical history.
    Patients (male or female) of reproductive potential must agree to use an effective
    method of contraception (as discussed with treating physician) from the time consent
    is signed, during study therapy, and for at least 90 days after the last dose of study
    therapy.
    Patients with prior malignancies are eligible if they have been disease-free for at
    least 5 years and are deemed by their physician to be at low risk for recurrence.
    Patients with squamous or basal cell carcinoma of the skin, melanoma in situ,
    carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that have
    been effectively treated are eligible, even if these conditions were diagnosed within
    5 years of randomization.

You may not be eligible for this study if the following are true:

  • Isolated, distant, or non-contiguous intra-abdominal metastases, even if resected.
    Colon cancer other than adenocarcinoma (e.g., sarcoma, lymphoma, carcinoid).
    Prior history of invasive adenocarcinoma of colon or rectum.
    Patients with active autoimmune disease. (Patients with endocrine autoimmune diseases
    requiring replacement therapy alone are allowed.)
    Gastroduodenal ulcer(s) determined by endoscopy to be active.
    Any malabsorption condition.
    Known history of human immunodeficiency virus (HIV) infection or chronic or active
    hepatitis B or hepatitis C requiring treatment with antiviral therapy.
    Any concomitant systemic therapy or radiation therapy initiated for this malignancy.
    Active infection, or chronic infection requiring chronic suppressive antibiotics.
    Persistent CTCAE v4.0 greater than or equal to grade 2 diarrhea regardless of
    etiology.
    Know history of allografts (including corneal transplant).
    Chronic daily treatment with corticosteroids with a dose of greater than or equal to
    10 mg/day methylprednisolone equivalent (excluding inhaled steroids), or any other
    immunosuppressive drugs.
    Any significant bleeding (greater than or equal to grade 3, hemorrhage) that is not
    related to the primary colon tumor within 6 months before randomization.
    Any of the following cardiac conditions:
    documented New York Heart Association (NYHA) Class III or IV congestive heart
    failure;
    myocardial infarction within 6 months prior to randomization;
    unstable angina (angina symptoms at rest) within less than or equal to 3 months
    prior to randomization; and
    clinically significant symptomatic arrhythmia despite anti-arrhythmic therapy.
    Uncontrolled blood pressure (systolic pressure greater than 150 mmHg or diastolic
    pressure greater than 90 mmHg on repeated measurements).
    Symptomatic brain or meningeal tumors.
    Patients with seizure disorder requiring medication.
    Presence of non-healing wound, non-healing ulcer, or bone fracture.
    Symptomatic interstitial lung disease or definitive evidence of interstitial lung
    disease described on CT scan, MRI, or chest x-ray in asymptomatic patients; dyspnea at
    rest requiring current continuous oxygen.
    Arterial or venous thrombotic or embolic events such as cerebral vascular accident
    (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism
    within 6 months before randomization (except for adequately treated catheter-related
    venous thrombosis occurring within 6 months before randomization).
    Symptomatic peripheral ischemia.
    Psychiatric or addictive disorders or other conditions or unresolved toxicities of
    prior therapy greater than grade 2 that, in the opinion of the investigator, would
    preclude the patient from meeting the study requirements, or interfere with
    interpretation of study results.
    Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be
    performed within 14 days prior to randomization according to institutional standards
    for women of childbearing potential.)
    Major surgery (including ostomy reversal), open biopsy or significant trauma injury,
    within 28 days prior to randomization.
    Anticipation of need for major surgical procedures during the course of study.
    Known hypersensitivity to study drug, study drug classes or excipients of the
    formulation.
    Use of any vascular endothelial growth factor (VEGF) targeted therapy or previous use
    of regorafenib.
    Patients taking strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4) who
    cannot interrupt therapy from the time the C-13 consent is signed through 30 days
    after the last dose of study therapy.
    Patients taking herbal remedies (e.g., St. John's Wort [Hypericum perforatum]) who
    cannot interrupt therapy from the time the C-13 consent is signed through 30 days
    after the last dose of study therapy.
    Use of immune modulators and/or any immunosuppressive drugs.
    Use of any investigational agent within 28 days of randomization.
    Patients receiving erythropoiesis-stimulating agents or other hematopoietic growth
    factors.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.